United States: New Approach For Biologic And Biosimilar Names

Last Updated: February 1 2017
Article by Christopher Betti and Jennifer Dienes

FDA final guidance will have significant impact on marketing of biologics, biosimilars and related products.

This month, FDA issued its final guidance on Nonproprietary Naming of Biological Products (Naming Guidance). The Naming Guidance represents a new framework for the entire category of biological products, including biosimilars. Instead of using nearly identical labeling for a biosimilar and its reference product, FDA now is requiring the use of a proper nonproprietary name (proper name) for each originator biological product, related biological and biosimilar product. The Proper Name will be a combination of a "core name" and a distinguishing suffix for each product which is composed of four lowercase letters devoid of any meaning. (Naming Guidance at 1.)

Notably, all previously licensed biologics under section 351(a) or 351(k) of the Public Health Service (PHS) Act will be renamed with a new suffix. (Id.) Also, the new requirement does not address how to designate interchangeability of biosimilars for which FDA is still considering the appropriate format. (Id.) FDA believes that the new framework will assist in pharmacovigilance efforts, avoid inadvertent substitution, and therefore prevent medication errors. The framework is also anticipated to ease use of the Purple Book which will group related products together, presumably facilitating easier comparisons among products.

The framework, which will have significant commercial implications, was published as a guidance document rather than a binding regulation. Therefore, there remains opportunity for further industry dialogue around the acceptability of the framework, especially as FDA leadership and policy change during the Trump administration. Further, the effective date of the guidance will be delayed at least 60 days as the White House and new agency heads review all recently issued guidances and regulations. See here the memorandum dated January 20, 2017, from Reince Priebus, Assistant to the President and Chief of Staff, to heads of the executive departments and agencies.


Originator biological products will have a core name that is the adopted name designated by the United States Adopted Names (USAN) Council for the relevant biological substance when available. (Id. at 7.) If the product is a related biological product, a biosimilar product, or an interchangeable product, the core name will be the same as the relevant previously licensed reference product. (Id. at 7-8.) The use of a common core name will indicate a relationship among the products. (Id. at 8.) FDA may also use an identifier attached as a prefix to distinguish some products from previously licensed products to help avoid medication errors and facilitate pharmacovigilance, e.g., ado-trastusumab emtansine vs.trastuzumab. (Id.)

For biological products previously licensed under the PHS Act, their revised proper name generally would include the original proper name serving as the "core name" followed by a distinguishing suffix attached with a hyphen. (Naming Guidance at 2.) While FDA is continuing to consider how implementation of this process will occur, it intends to assign distinguishing suffixes to a group of previously licensed products. (Id.) However, FDA will also accept submissions of prior-approval labeling supplements to Biologics Licensing Applications (BLAs) containing up to 10 proposed suffixes and any supporting analyses demonstrating the proposed suffixes are unique, devoid of meaning, and not false or misleading. (Id. at 2, 9.) Notably, the suffixes will not be allowed to use any symbols or numbers, other than a hyphen. The suffix will also not be allowed to look similar to or otherwise connote the name of the license holder. (Id. at 10).

Going forward, an applicant (either under section 351(a) or 351(k) of the PHS Act) should propose a suffix comprising four lowercase letters to use as the distinguishing identifier in the FDA-designated proper name. (Id. at 9.) Submission of up to 10 proposed suffixes in order of preference can be made no earlier than the request for a pre-BLA meeting for biologics, or for biosimilars; the request for the biosimilar development type 4 meeting. (Id.) Any supporting analyses of the proposed suffixes should also be included for FDA's consideration. (Id.)

The timing of the requests will avoid a race by the applicant to file early for suffixes to establish market position (e.g., "ab" suffixes presumably would be listed in formularies or other compilations before "xy" suffixes). There is no discussion in the guidance about appeal mechanisms or process in the event that two or more applicants seek the same suffix. If the applicant does not submit an acceptable suffix by the time of product approval, FDA may elect to choose the suffix.


A. Enhanced Pharmacovigilance

FDA stated that the suffix approach should help ensure patient safety by enhancing its ability to track adverse events to a specific manufacturer and "allow surveillance systems to detect safety signals throughout the life cycle of a product." (Naming Guidance at 4.) This will enable targeted remedial action to address any concerns and avoid implicating a broader group of products that do not have similar problems. (Id.) The use of proper names with distinguishing suffixes will assist in pharmacovigilence efforts by identifying specific products in spontaneous adverse event reporting as FDA's current experience is that proprietary names and National Drug Code (NDC) numbers are rarely used to report adverse events, and may be changed over time by license holders. (Id. at 5.)

FDA also notes that the use of distinguishing suffixes will "reinforce accurate product identification in billing and claims records used for active pharmacovigilance" (Id.) This will also make it easier for government healthcare programs to track purchasing and pricing patterns around these products.

B. Avoidance of Inadvertent Substitution

FDA also stated that its proposed naming convention will help prevent "inadvertent substitution," which could include unintentional switching between biological products not determined by FDA to be interchangeable. (Id.) FDA is concerned that if originator biological products, related biological products, and biosimilar products all share a proper name, inadvertent substitution could lead to medication errors, including providing a patient with a product having a different delivery system or route of administration from what was prescribed, leading to confusion and dosing errors. (Id. at 6.) The use of the same proper name could also cause confusion amongst healthcare providers, who might incorrectly assume that all products with the same proper name are interchangeable. (Id.) FDA did not cite any support for these concerns, however.

C. Avoidance of Inaccurate Perceptions

FDA stated that the use of an FDA-designated suffix in biological products' nonproprietary name will avoid inaccurate perceptions of the safety and effectiveness of biological products. (Id. at 7.) FDA believed that applying the suffix naming convention only to those biological products licensed under section 351(k) of the PHS Act would create the false impression that biosimilar products were different from their reference products in some clinically meaningful way or somehow inferior to their reference products. (Id.) FDA also noted that there may be confusion among healthcare providers in using biological products based on their historical use of small molecule drugs and their generic versions.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Patterson Belknap Webb & Tyler LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Patterson Belknap Webb & Tyler LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions